- Home
- ARQT vs ELVN Comparison
ARQT vs ELVN Comparison
Compare ARQT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | ELVN |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 1.1B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARQT | ELVN |
|---|---|---|
| Price | $28.13 | $15.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $24.83 | ★ $41.20 |
| AVG Volume (30 Days) | ★ 2.2M | 708.2K |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $317,929,000.00 | N/A |
| Revenue This Year | $85.51 | N/A |
| Revenue Next Year | $30.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.21 | N/A |
| 52 Week Low | $11.13 | $13.30 |
| 52 Week High | $31.77 | $25.37 |
Technical Indicators
Market Signals| Indicator | ARQT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 30.93 |
| Support Level | $28.30 | $16.62 |
| Resistance Level | $31.77 | $20.47 |
| Average True Range (ATR) | 1.11 | 1.43 |
| MACD | -0.54 | -0.56 |
| Stochastic Oscillator | 1.34 | 2.49 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.